Ivemend

RSS

fosaprepitant

Authorised
This medicine is authorised for use in the European Union.

Overview

Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.

It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.

It contains the active substance fosaprepitant.

This EPAR was last updated on 26/08/2022

Authorisation details

Product details
Name
Ivemend
Agency product number
EMEA/H/C/000743
Active substance
fosaprepitant
International non-proprietary name (INN) or common name
fosaprepitant
Therapeutic area (MeSH)
  • Vomiting
  • Cancer
Anatomical therapeutic chemical (ATC) code
A04AD12
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Revision
24
Date of issue of marketing authorisation valid throughout the European Union
11/01/2008
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

25/08/2022 Ivemend - EMEA/H/C/000743 - N/0048

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antiemetics and antinauseants

Therapeutic indication

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.

Ivemend 150 mg is given as part of a combination therapy.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating